Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/10/?d=1Neue Studien: Europe PMCdeRole of real-world evidence from patient registries for psoriasis in decision-making: a systematic review.https://www.psoriasis-news.de/articles.html/1_articles/role-of-real-world-evidence-from-patient-registries-for-psoriasis-in-decision-making-a-systematic-review-r409/IntroductionTreatment of moderate to severe psoriasis typically requires the use of multiple systemic therapies over a patient's lifetime. The efficacy and safety of systemic treatments are typically evaluated in clinical trials; however, patient registries are increasingly used to monitor long-term outcomes of systemic therapies for psoriasis in real-world settings. Psoriasis registries also generate important real-world evidence about psoriasis treatment that may facilitate a greater understanding of outcomes outside of a controlled clinical trial setting. This study thus characterises the design and measures used in real-world studies of psoriasis treatment from patient registries and assesses its use in informing clinical guidelines and reimbursement decisions.

Methods and analysis

A systematic literature review was conducted to identify real-world observational studies that used psoriasis registry data. PubMed and Embase were searched for English-language studies published between January 2018 and January 2023. To assess how real-world studies, clinical guidelines, and reimbursement and coverage reports have informed practice, treatment, and reimbursement guidelines, a narrative review of recommendations was conducted. All results were screened by two independent reviewers (LP and TAS) using prespecified inclusion and exclusion criteria. Outcomes of interest were extracted into Excel, with all conflicts resolved through discussion/consensus. Tables displayed outcomes and research topics first by year, then by registry.

Prospero registration number

CRD42023402431.

Weiterlesen

]]>409Sun, 25 Jan 2026 18:42:10 +0000Network pharmacology-based elucidation of the regulatory mechanism of Solanum lyratum (Bai Ying) against psoriasis via the IL-17A/STAT3 axis: Molecular docking and HaCaT cell validation.https://www.psoriasis-news.de/articles.html/1_articles/network-pharmacology-based-elucidation-of-the-regulatory-mechanism-of-solanum-lyratum-bai-ying-against-psoriasis-via-the-il-17astat3-axis-molecular-docking-and-hacat-cell-validation-r408/BackgroundPsoriasis affects approximately 2% of the global population, with the IL-17A-STAT3 pathway mediating abnormal keratinocyte proliferation and inflammatory amplification. Solanum lyratum (Bai Ying) has long been used for skin disorders, and its steroidal alkaloids have anti-inflammatory potential, though the mechanisms remain unclear.

Objective

To elucidate the molecular basis and cytological efficacy of S. lyratum steroidal alkaloids in exerting anti-psoriatic effects via the IL-17A/STAT3 axis.

Methods

HPLC-MS-QTOF, network pharmacology, molecular simulation, and a HaCaT cell model with STAT3-siRNA assays were employed.

Results

Eighteen components were identified; steroidal alkaloids showed high affinity for STAT3 and IL17RA. S. lyratum (5-40 μg/mL) enhanced cell viability, inhibited p-STAT3 (IC50 = 14.30 μg/mL), and attenuated inflammatory responses and keratinocyte proliferation.

Conclusion

S. lyratum steroidal alkaloids exert dual-targeted blocking effects on the IL-17A/STAT3 axis, supporting it as a potential therapeutic candidate for psoriasis.

Weiterlesen

]]>408Sun, 25 Jan 2026 18:42:10 +0000Beyond the skin: Lived experiences and coping strategies of psoriasis patients in Malaysia.https://www.psoriasis-news.de/articles.html/1_articles/beyond-the-skin-lived-experiences-and-coping-strategies-of-psoriasis-patients-in-malaysia-r407/BackgroundPsoriasis is a chronic autoimmune skin condition that significantly impacts an individual's quality of life, resulting in physical discomfort, psychological distress, and compromised social well-being. However, there is limited understanding regarding the challenges faced by patients in Malaysia. This study examines the lived experiences of patients with psoriasis in Malaysia, focusing on the emotional, social, financial, and treatment-related challenges they face, as well as the coping mechanisms they employ.

Methods

A qualitative, phenomenological approach was employed among members of the Psoriasis Association Malaysia. Purposive sampling was used to recruit adult participants who were capable of participating in the online interview. Data collection involved the use of Google Forms, which included the Malay version of the Dermatology Life Quality Index questionnaire, supplementing the qualitative findings. This was followed by semi-structured online interviews conducted via video conferencing. Thematic analysis was conducted using NVivo version 14, and descriptive analysis was performed using SPSS version 28.

Result

This study involved 30 respondents with a mean age of 44 years diagnosed with psoriasis. The mean (SD) for the duration of illness is 21.3 (11.8) years. About 70% respondents reported that psoriasis had a moderate to very high impact on their quality of life. Thematic analysis has identified six major themes, including physical devastation, emotional burden, disruption in social functioning, treatment hurdles and advancements, financial barriers, and behavioral adaptation.

Conclusion

Psoriasis imposes complex challenges that extend beyond physical symptoms, affecting emotional well-being, social interactions, financial stability, and treatment struggles. In response to the various challenges that arose, respondents developed behavioral adaptations to achieve a better quality of life. Framed within the biopsychosocial model, the findings emphasize the need for a holistic, patient-centred approach to psoriasis care that integrates medical treatment with psychological support and social interventions to improve overall quality of life.

Weiterlesen

]]>407Sun, 25 Jan 2026 18:42:10 +0000Unsaturated Fatty Acid Metabolic Reprogramming in Psoriatic Skin Drives Inflammation and Predicts Response to Biologic Therapy.https://www.psoriasis-news.de/articles.html/1_articles/unsaturated-fatty-acid-metabolic-reprogramming-in-psoriatic-skin-drives-inflammation-and-predicts-response-to-biologic-therapy-r406/PurposePsoriasis is frequently associated with dyslipidemia, yet the role of specific unsaturated fatty acid (UFA) metabolic pathways in disease pathogenesis and treatment response remains poorly understood. This study aimed to characterize the landscape of UFA metabolic reprogramming in psoriasis and evaluate its clinical relevance for predicting response to biologic therapy.

Patients and methods

We performed an integrated multi-omics analysis incorporating transcriptomic data from human psoriatic lesions, single-cell RNA sequencing, and lipidomic profiling. Gene set variation analysis (GSVA) was used to evaluate UFA pathway activity. Logistic regression and LASSO were employed for biomarker selection and predictive modeling.

Results

We identified eight significantly dysregulated UFA metabolic pathways in psoriatic lesions, six of which were associated with key pathogenic processes in psoriasis. All pathways were reversibly modulated by biologic agents targeting TNF-α, IL-12/23, and IL-17A. We derived a three-gene biomarker signature (PLA2G4D, PLA2G4A, and FADS2) that robustly predicts response to IL-12/23 inhibition prior to treatment initiation (AUC = 0.902). Single-cell RNA sequencing revealed keratinocytes as the primary cellular contributors to UFA metabolism and identified an expanded PLA2G4D-high keratinocyte subpopulation in psoriatic skin, which was associated with the accumulation of Lysophosphatidylcholine (LysoPC) and Lysophosphatidylethanolamine (LysoPE).

Conclusion

Our findings elucidate the pathway-level metabolic basis of psoriasis inflammation and provide a clinically applicable tool for predicting response to biologic therapy. The results highlight the importance of UFA metabolic reprogramming in psoriatic pathogenesis and offer new avenues for treatment personalization.

Weiterlesen

]]>406Mon, 29 Dec 2025 19:17:49 +0000Preparation of Tanshinone IIA and glycyrrhetinic acid emulsion and preliminary study on its anti-psoriasis efficacy.https://www.psoriasis-news.de/articles.html/1_articles/preparation-of-tanshinone-iia-and-glycyrrhetinic-acid-emulsion-and-preliminary-study-on-its-anti-psoriasis-efficacy-r405/AimThe current work highlighted the preparation method of Tanshinone IIA, Glycyrrhetinic acid Emulsion with eutectic (GT-eEmu) and investigated its effectiveness in the internal and external treatment of psoriasis.

Materials & methods

The optimal prescription ratios of the emulsions were screened based on single-factor and orthogonal experiments, in which the appearance, particle size, centrifugal stability, and placement stability of the emulsion were used as indicators. On this basis, the maximum drugs loading was determined and optimized by D-optimal. Then the gloss, consistency, uniformity, spreading, and centrifugal stability of the emulsion gel were used as indicators to screen the best preparation method of the emulsion gel. The gastrointestinal stability of GT-eEmu and the original drug was evaulated by the artificial gastrointestinal fluid test, while the irritation to the the gastrointestinal mucosa was investigated after treatment. In addition, the skin permeability and skin side effects of the preparation were studied. Finally, the therapeutic effects of various preparations on psoriasis in mice were studied based on PASI scores, HE pathological sections and the expression of SOCS1 and STAT3.

Results

The best optimized prescription of GT-eEmu was: oil phase 7%, emulsifier 4.5%, and emulsification temperature 60 ℃, where the drug loading of TSN IIA and GA were 0.17 and 0.70 g·L- 1. The best preparation method for GT-eEmu-Gel was to add carbomer 980 with 6% gel matrix to the emulsion prepared by the optimized method, followed by mixing with triethanolamine and adjusting the pH to 6.0-7.0 to prepare a 0.5% carbomer matrix emulsion. The gastrointestinal stability experiment showed that the addition of eutectic ingredients did not cause significant irritation to the gastrointestinal tract, while the good permeability and sustained release of GT-eEmu-Gel were shown by in vitro release assays and the emulsion gel form could further reduce the irritation of eutectic to the skin. Finally, imiquimod-induced psoriasis animal model experiments indicated that GT-eEmu and its gel could reduce the degree of skin lesions and histopathological changes in model mice, and decrease the average expression of SOCS1 and STAT3, which indicated these preparation had therapeutic effects on psoriasis. Additionally, the "internal and external treatment" group had the best effect compared with the oral-only group, while there was a significant difference (P < 0.01) compared with the model group.

Conclusion

The preparation process of GT-eEmu and GT-eEmu-Gel is stable and quality-controlled, which can improve the oral bioavail ability of both drugs to different degrees and reduce the irritation to the skin. The results showed that they have certain therapeutic effects on psoriasi, which can be safely administered orally and applied externally on the skin. At the same time, compared with the single treatment, the "internal and external combined treatment" method was the most effective, which indicates the concept of "internal and external combined treatment" method has practical significance.

Weiterlesen

]]>405Mon, 29 Dec 2025 19:17:49 +0000Prevalence of tobacco smoking and its association with disease severity and psoriatic arthritis among patients with nail psoriasis in China: a cross-sectional study.https://www.psoriasis-news.de/articles.html/1_articles/prevalence-of-tobacco-smoking-and-its-association-with-disease-severity-and-psoriatic-arthritis-among-patients-with-nail-psoriasis-in-china-a-cross-sectional-study-r404/IntroductionNail psoriasis is a common, treatment-refractory manifestation of psoriasis. Smoking is a key environmental factor implicated in nail and articular psoriasis. While smoking's association with cutaneous psoriasis is well-studied, its relationship with nail psoriasis remains less explored.

Objective

The primary objective of this study was to investigate the impact of smoking on the severity of nail psoriasis and arthritic psoriasis in patients with nail psoriasis.

Methods

Data from 1044 nail psoriasis patients within a population-based registry in China were analyzed. We assessed associations of smoking status and intensity with sociodemographics, disease severity and dermatology quality of life measures (including PASI, BSA, DLQI, and PEST scores), and PsA diagnosis. Analyses used SPSS 29.0; p < 0.05 defined significance.

Results

The current smoking rate among patients with nail psoriasis is 34.6%, which is much higher than the current smoking rate among patients without nail psoriasis (20.2%). The proportions of the three different smoking intensities are also much higher than those among patients without nail psoriasis. Current smoking affects the total nail involvement count in patients with nail psoriasis, and severe smoking affects both the total nail involvement count and the nails with > 90% area involvement count in these patients. However, we found that smoking intensity was negatively correlated with DLQI scores in nail psoriasis, which is contrary to previous studies on plaque psoriasis. Spearman's correlation analysis revealed that smoking intensity and smoking index were positively associated with total nail involvement count and individual nails > 90% with area involvement count. In the regression analysis for PSA, the OR for current smokers was 0.57 (95% CI: 0.35-0.92) compared to non-smokers, and the OR for severe smokers was 0.37 (95% CI: 0.15-0.90) compared to mild smokers.

Conclusion

Patients with nail psoriasis have higher smoking rates and smoking intensity compared to those without nail psoriasis. The total nail involvement count was higher in current smokers than in non-smokers. Smoking intensity was positively associated with total nail involvement count and individual nails with > 90% area involvement count. Current smoking was a negative associated factor for PEST risk level. Both current smoking and severe smoking were negative associations with the presence of psoriatic arthritis.

Weiterlesen

]]>404Mon, 29 Dec 2025 19:17:49 +0000Understanding Cumulative Life Course Impairment in Canadian Patients With Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/understanding-cumulative-life-course-impairment-in-canadian-patients-with-psoriasis-r403/Weiterlesen

]]>403Sat, 27 Dec 2025 18:01:44 +0000Assessing internal construct validity of DAPSA and DAPSA28 in psoriatic arthritis: a European observational study using confirmatory factor analysis and additional psychometric testing.https://www.psoriasis-news.de/articles.html/1_articles/assessing-internal-construct-validity-of-dapsa-and-dapsa28-in-psoriatic-arthritis-a-european-observational-study-using-confirmatory-factor-analysis-and-additional-psychometric-testing-r402/ObjectivesThe Disease Activity index for Psoriatic Arthritis (DAPSA) was developed to assess disease activity in patients with psoriatic arthritis (PsA). A modified version, DAPSA28, uses 28 joints instead of 66/68. This study evaluated key psychometric properties of DAPSA and DAPSA28.

Methods

Data from 1865 patients with PsA in the European Spondyloarthritis (EuroSpA) Research Collaboration Network, having DAPSA and DAPSA28 scores at baseline and follow-up, were analysed. Tests included assessment of internal construct validity by scree plots, confirmatory factor analysis (CFA) and structural equation modelling (SEM), supplemented by tests of differential item functioning (DIF) and evaluation of internal consistency reliability by Cronbach's α (CA). A subset of 625 patients was used for most analyses, except descriptive statistics, correlation matrix and CA.

Results

One-dimensional CFA models for DAPSA and DAPSA28 showed acceptable model fit at baseline (root mean square error of approximation, RMSEA: 0.020, 0.034). However, model fit at 6 months follow-up was poor (RMSEA: 0.057, 0.063). SEM combining baseline and follow-up data could not identify an acceptable model fit. DIF was found for sex and country. CA indicated acceptable internal consistency (DAPSA: 0.65; DAPSA28: 0.63). Heterogeneity across countries was observed.

Conclusions

Overall, the model fit was acceptable across model fit statistics, supporting internal construct validity, but some evidence of misfit at country level was disclosed. Our findings support acceptable internal consistency reliability, but DIF was found for sex and country. Based on mixed results of model fit and DIF, further investigation of these and other PsA disease activity measures is warranted.

Weiterlesen

]]>402Sat, 27 Dec 2025 18:01:44 +0000To Explore the Mechanism of Cuproptosis in Psoriasis Based on Bioinformatics and in vivo Experiments.https://www.psoriasis-news.de/articles.html/1_articles/to-explore-the-mechanism-of-cuproptosis-in-psoriasis-based-on-bioinformatics-and-in-vivo-experiments-r401/PurposeTo explore the mechanism of cuprotosis in psoriasis, screen cuprotosis related genes (PDCRGs) in psoriasis, and provide new targets for precise diagnosis and treatment of psoriasis.

Material and methods

Integrate bioinformatics analysis and experimental validation. Firstly, based on the GEO database (GSE161683, GSE166388, GSE277173), differentially expressed genes (DEGs) and weighted gene co-expression network analysis (WGCNA) in psoriasis were screened; Identification of differential cuprotosis related genes (PDCRGs) in psoriasis using a self built cuprotosis gene database (1098 CRGs); Screen key PDCRGs through PPI network, machine learning, and ROC analysis. Subsequently, a mouse model of psoriasis induced by imiquimod (IMQ) was constructed, and gene expression, copper ion levels, inflammatory factors, and oxidative stress factors were validated using qPCR, Western blot, immunohistochemistry, fluorescence, and ELISA.

Results

Thirty-four PDCRGs were identified, among which STAT1, DLD, GBP1, CXCL10, PDHB, and LIAS are Hub genes. Machine learning and ROC analysis further identified APOL6, CD274, and LIAS as key diagnostic biomarkers. PDCRGs are significantly enriched in the TCA cycle, copper ion transport, and glucose metabolism pathways. The levels of FDX1 and serum copper ions were increased in the skin lesions of psoriasis mice, accompanied by upregulation of TCA cycle key proteins and PDCRGs expression; Copper overload triggers oxidative stress and inflammation cascade.

Conclusion

APOL6, CD274, and LIAS were screened as cuprotosis markers in psoriasis. Overexpression of these PDCRGs in psoriasis model mice can promote copper ion accumulation and interfere with the TCA cycle, increase oxidative stress and inflammation levels, and ultimately lead to the occurrence of psoriasis. Therefore, targeted intervention of cuprotosis is of great significance for the clinical treatment of psoriasis.

Weiterlesen

]]>401Sat, 27 Dec 2025 18:01:44 +0000Antibodies Targeting Gasdermin E as a Potential Therapeutic Option for Psoriasis - A Pilot Study on a Mouse Model.https://www.psoriasis-news.de/articles.html/1_articles/antibodies-targeting-gasdermin-e-as-a-potential-therapeutic-option-for-psoriasis-a-pilot-study-on-a-mouse-model-r400/BackgroundPsoriasis is a frequent and complex dermatosis of uncertain origin. A few years ago, a family of gasdermin proteins was implicated in psoriasis pathogenesis. Although the number of therapeutic options for psoriasis is growing, considering the burden of the disease, treatment personalization, and the possibility of side effects or loss of the drug's efficacy, it is important to seek new therapeutic targets.

Objective

The aim of this study was to assess the efficacy of antibodies against gasdermin E (GSDME) in the treatment of psoriatic lesions.

Methods

The study involved 30 male BALB/c mice, 8 weeks old. 5% imiquimod cream was applied topically on the skin to induce psoriatic lesions. The next day after the psoriatic lesions appeared, the antibodies were administered. Mice from the study group received the rabbit polyclonal anti-GSDME antibody intravenously or intraperitoneally. The control group was administered sterile 0.9% saline solution.

Results

The injection of anti-GSDME antibodies to mice with imiquimod-induced psoriasis resulted in the resolution of skin lesions, whereas the injection of saline to the control group did not result in significant changes.

Conclusion

Antibodies targeting GSDME seem to be promising therapeutic agents in psoriasis; however, their utility has to be confirmed in future studies.

Weiterlesen

]]>400Sat, 27 Dec 2025 18:01:44 +0000Association of Sociodemographic Factors and Mental Health Utilization for Psoriasis Patients in the Medical Expenditure Panel Survey.https://www.psoriasis-news.de/articles.html/1_articles/association-of-sociodemographic-factors-and-mental-health-utilization-for-psoriasis-patients-in-the-medical-expenditure-panel-survey-r399/BackgroundPsoriasis is associated with increased psychiatric comorbidity, yet patterns of mental health care use and spending remain unclear.

Objective

To characterize use and expenditures for outpatient mental health services and psychotropic medications among U.S. persons with psoriasis and identify sociodemographic disparities.

Methods

Cross-sectional analysis of 2,123 participants with psoriasis in the 2005-2022 Medical Expenditure Panel Survey. Negative binomial and two-part models examined associations between sociodemographic characteristics and mental health care utilization and spending.

Results

Higher education and income levels were associated with fewer psychiatrist visits, but lower-income groups had greater utilization overall. Men spent more on psychotropic medications than women. Racial minorities had lower medication spending than White patients. Medicare coverage was linked to greater total expenditure compared to private insurance.

Limitations

Psoriasis severity was unavailable. International Classification of Diseases-based identification may undercount cases.

Conclusion

Substantial sociodemographic and insurance disparities persist in mental health care use and spending among psoriasis patients.

Weiterlesen

]]>399Sat, 27 Dec 2025 18:01:44 +0000Factors influencing quality of life in patients with psoriasis: A large cross-sectional study.https://www.psoriasis-news.de/articles.html/1_articles/factors-influencing-quality-of-life-in-patients-with-psoriasis-a-large-cross-sectional-study-r398/BackgroundPsoriasis is a systemic disease that brings enormous mental pressure and economic burden to patients and has a significant impact on patients' quality of life (QoL). This study aimed to explore factors affecting the dermatology life quality index (DLQI) in patients with psoriasis.

Methods

This retrospective cross-sectional study used data sourced from the Psoriasis Diagnosis and Treatment Real-world Database, and 8839 patients with psoriasis (recruited between June 24, 2020 and September 2, 2021) were included. Demographic and clinical characteristics and DLQI scores were retrospectively analyzed, and correlations between DLQI score and age, disease course, psoriasis area and severity index (PASI) score were calculated. Regression analysis was conducted to explore the factors affecting the DLQI scores of patients with psoriasis.

Results

The average DLQI scores were significantly higher in young (8.58 ± 7.22) and middle-aged individuals (8.09 ± 6.61) than those in juveniles (6.00 ± 5.79) and older individuals (7.39 ± 6.29) (P = 1.70E-15). The average DLQI scores gradually decreased among individuals whose work status were unemployment (10.4 ± 7.83), part-time (9.02 ± 6.83), full-time (8.43 ± 6.90), retired (7.93 ± 6.07), and students (7.10 ± 6.31) (P = 9.82E-23). Except for those with disease course ≥20 years, DLQI scores increased gradually with prolongation of the disease course (P = 4.72E-22). The higher the severity of psoriasis, the higher the average DLQI score (P = 3.79E-113). The presence of psoriatic lesions at the exposed sites significantly affected DLQI scores (P <0.001). The average DLQI scores were significantly higher among individuals with nail holes, joint pain, and comorbidities than among those without these conditions (P <0.05). Correlation analysis indicated that the PASI scores were positively correlated with the DLQI scores (r = 0.26, P = 4.19E-134). Multinomial logistic regression analysis showed significant influencing factors (excluding comorbidity) with different degrees of impact based on the DLQI score (P <0.05).

Conclusion

Physicians should focus on significant factors, such as sex, age, marital status, education, work status, sub-types, disease course, PASI score, without joint pain, and without nail holes, to improve the QoL of patients with psoriasis.

Weiterlesen

]]>398Sat, 27 Dec 2025 18:01:44 +0000Neuroimmune Crosstalk in Psoriasis: Mechanisms and Therapeutic Implications.https://www.psoriasis-news.de/articles.html/1_articles/neuroimmune-crosstalk-in-psoriasis-mechanisms-and-therapeutic-implications-r397/No abstract supplied.

Weiterlesen

]]>397Sat, 27 Dec 2025 18:01:44 +0000Evaluating the Body Roundness Index as a Novel Digital Biomarker for Psoriasis Risk Prediction: Cross-Sectional Study.https://www.psoriasis-news.de/articles.html/1_articles/evaluating-the-body-roundness-index-as-a-novel-digital-biomarker-for-psoriasis-risk-prediction-cross-sectional-study-r396/BackgroundPsoriasis is a chronic inflammatory skin disorder that has been increasingly linked to metabolic imbalances, particularly obesity. Conventional anthropometric indicators such as BMI and waist circumference (WC) may not sufficiently capture body fat distribution or reflect metabolic risk. The body roundness index (BRI), which integrates both height and waist measurements, has emerged as a potentially superior metric, though its relevance to psoriasis risk remains underexplored.

Objective

This study aimed to investigate the use of BRI as a digital biomarker for assessing psoriasis risk and to compare its predictive strength against BMI and WC across various demographic and metabolic subgroups using data from a nationally representative sample.

Methods

A cross-sectional analysis was conducted using data from 13,798 adults aged 20 to 59 years who participated in the National Health and Nutrition Examination Survey between 2003 and 2006 as well as between 2009 and 2014. Psoriasis status was self-reported. Anthropometric measures (BRI, BMI, and WC) were calculated from standardized physical assessments. Weighted multivariable logistic regression models and restricted cubic spline analyses were used to examine associations while adjusting for demographic, metabolic, and lifestyle variables. A nomogram was constructed to quantify the relative predictive contributions of each metric.

Results

BRI exhibited a strong linear association with psoriasis risk (odds ratio [OR] 1.11 per unit increase, 95% CI 1.05-1.17; P<.001), outperforming BMI (OR 1.03) and WC (OR 1.01). Tertile analysis revealed a 1.73-fold increased risk of psoriasis in the highest BRI group (P=.003). Subgroup analyses confirmed consistent associations across age, sex, race or ethnicity, and metabolic status (P for interaction >.05). The nomogram highlighted BRI as the most influential predictor, indicated by its broad scoring range.

Conclusions

BRI shows stronger and more consistent associations with psoriasis risk than BMI or WC, supporting its potential role as a digital biomarker for early risk stratification. Incorporating BRI into clinical decision-making tools may enhance personalized approaches to psoriasis prevention and management.

Weiterlesen

]]>396Sat, 27 Dec 2025 18:01:44 +0000Inflammation mediation of the association between brominated flame retardants and psoriasis among U.S. adultshttps://www.psoriasis-news.de/articles.html/1_articles/inflammation-mediation-of-the-association-between-brominated-flame-retardants-and-psoriasis-among-us-adults-r395/No abstract supplied.

Weiterlesen

]]>395Sat, 27 Dec 2025 18:01:44 +0000Interface-Engineered Nanocarriers for Translational and Patient-Centric Topical Therapy in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/interface-engineered-nanocarriers-for-translational-and-patient-centric-topical-therapy-in-psoriasis-r394/Weiterlesen

]]>394Sat, 27 Dec 2025 18:01:44 +0000Non-invasive transdermal delivery of peptide inhibitors of the IL-23/IL-17 axis by novel ionic liquid biomaterials for psoriasis treatment.https://www.psoriasis-news.de/articles.html/1_articles/non-invasive-transdermal-delivery-of-peptide-inhibitors-of-the-il-23il-17-axis-by-novel-ionic-liquid-biomaterials-for-psoriasis-treatment-r393/e.g., susceptibility to degradation, large molecular size, hydrophobicity and charge. Herein, we used novel ionic liquid biomaterials, amino acid esters and octanoic acids, as a non-invasive transdermal drug delivery system for bicyclic peptide inhibitors targeted to IL-23R and IL-17A. Using phenotypical images, psoriasis area and severity index, hematoxylin-eosin, and immunohistochemistry, we demonstrate that a biocompatible ionic liquid-based topical delivery approach of peptide inhibitors alleviates psoriasis in an imiquimod-induced psoriasis mouse model. Flow cytometry of innate lymphoid cells (ILCs) within the spleen, peripheral blood, and lesional epidermis shows that treatment with ionic liquids-peptides selectively blocks and reconfigures the spectrum of skin-resident and circulating ILCs. These results provide a framework for a topical delivery approach for peptides. Our findings highlight the potential of topical administration of peptide inhibitors of the IL-23/IL-17 pathway by biocompatible ionic liquids to treat psoriasis. The main immunopathogenic mechanism of peptide inhibitors mitigating psoriasis is reconfiguration of a spectrum of skin-resident and circulating ILCs.

Weiterlesen

]]>393Sun, 21 Dec 2025 14:44:00 +0000Integrative bioinformatics-machine learning-experimental validation identifies shared immunomodulatory targets in psoriasis and psoriatic arthritis and deciphers allicin's therapeutic mechanism.https://www.psoriasis-news.de/articles.html/1_articles/integrative-bioinformatics-machine-learning-experimental-validation-identifies-shared-immunomodulatory-targets-in-psoriasis-and-psoriatic-arthritis-and-deciphers-allicins-therapeutic-mechanism-r392/Weiterlesen

]]>392Sun, 21 Dec 2025 14:44:00 +0000Dietary habits, nutritional supplement use, and adherence to national dietary guidelines in patients with psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/dietary-habits-nutritional-supplement-use-and-adherence-to-national-dietary-guidelines-in-patients-with-psoriasis-r391/Weiterlesen

]]>391Sun, 21 Dec 2025 14:44:00 +0000Impact of weight-loss interventions on psoriasis severity: A systematic review and meta-analysis.https://www.psoriasis-news.de/articles.html/1_articles/impact-of-weight-loss-interventions-on-psoriasis-severity-a-systematic-review-and-meta-analysis-r390/BackgroundPsoriasis affects at least 60 million people worldwide, and 80% also live with overweight or obesity. Excess weight increases susceptibility to psoriasis and is associated with more severe disease.

Objective

To evaluate the impact of weight-loss interventions on psoriasis severity (Psoriasis Area and Severity Index [PASI], PASI50, PASI75, PASI100 [50%/75%/100% reduction in baseline PASI, respectively]) and quality of life (Dermatology Life Quality Index [DLQI]).

Methods

We systematically searched five databases and two trial registries (inception to 03/09/2025). Outcomes were informed by patient focus-group discussions. Randomized controlled trials (RCTs) in adults with psoriasis, comparing any weight-loss intervention versus usual care or a lower-intensity weight-loss intervention, were included. Studies had to report a change in weight and ≥1 psoriasis severity or quality-of-life measure. Random effects meta-analyses were used.

Results

Thirteen RCTs (1145 participants) with 14 comparisons were included. Eleven interventions advised dietary changes, of which four included physical activity. Three used weight-loss medications. Across 14 comparisons (n = 1145, mean difference (MD) in weight change: -6.7 kg), weight-loss interventions produced a greater reduction in PASI versus control: MD -2.5 (95%CI: -3.8 to -1.1, I2 = 85.2%). We found a significant effect of weight-loss interventions on the likelihood of achieving PASI75 (RR = 1.6, 95%CI: 1.1-2.2, I2 = 22.6% [based on six comparisons, n = 681, MD in weight change: -7.3 kg]). There was no statistically significant effect of the interventions on the likelihood of achieving PASI50 (RR = 1.5, 95%CI: 0.9-2.4, I2 = 72.8% [based on four comparisons, n = 509, MD in weight change: -4.0 kg]) or PASI100 (RR = 1.6, 95%CI: 0.3-9.7, I2 = 0.0% [based on two comparisons, n = 334, MD in weight change: -5.2 kg]), but both analyses were limited by few studies. Across seven comparisons (n = 364; MD in weight change -7.8 kg), weight-loss interventions were associated with a significant improvement in DLQI compared to control: MD -5.0 (95%CI: -9.7 to -0.3, I2 = 96.0%).

Conclusion

High-certainty evidence suggests weight-loss interventions can improve psoriasis severity and quality of life, and should be considered as part of routine treatment.

Weiterlesen

]]>390Sun, 21 Dec 2025 14:44:00 +0000Beyond trauma: Schema-driven psychological burden in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/beyond-trauma-schema-driven-psychological-burden-in-psoriasis-r389/Weiterlesen

]]>389Sun, 21 Dec 2025 14:44:00 +0000Sex-specific associations between nutritional status, disease activity, and fatigue in psoriatic arthritis: a cross-sectional analysis.https://www.psoriasis-news.de/articles.html/1_articles/sex-specific-associations-between-nutritional-status-disease-activity-and-fatigue-in-psoriatic-arthritis-a-cross-sectional-analysis-r388/ObjectiveThe purpose of this study was to evaluate the relationship between nutritional status-assessed by the Controlling Nutritional Status (CONUT) score-and disease activity, fatigue, and sleep quality in patients with psoriatic arthritis (PsA), with attention to sex-specific differences.

Methods

113 adults with PsA were included in this cross-sectional study. Nutritional status was classified as normal (CONUT 0-1) or malnutrition (CONUT ≥ 2). Disease activity was assessed using the Disease Activity in Psoriatic Arthritis (DAPSA) score, fatigue using the Fatigue Severity Scale (FSS), and sleep quality using the Jenkins Sleep Scale (JSS). Correlation and ROC analyses were performed.

Results

Malnutrition was identified in 18.6% of patients. Compared to those with normal nutritional status, malnourished patients had higher CRP (12.8 vs. 6.4 mg/L, p = 0.012) and lower albumin and lymphocyte levels (p < 0.001). High disease activity (DAPSA > 28) was more common in the malnutrition group (38.1% vs. 15.2%, p = 0.029). The CONUT score correlated with DAPSA (Rho = 0.327, p < 0.001), CRP (Rho = 0.422, p < 0.001), and fatigue severity (Rho = 0.186, p = 0.048). No association was observed with sleep quality. ROC analysis showed that CONUT ≥ 2 predicted high disease activity (AUC 0.70). In sex-stratified analyses, correlations with DAPSA and fatigue were present only in females.

Conclusion

Higher CONUT scores were associated with greater disease activity and fatigue among patients with psoriatic arthritis. These results underscore the potential value of incorporating routine nutritional evaluation into the comprehensive management of PsA.

Weiterlesen

]]>388Sun, 21 Dec 2025 14:44:00 +0000The Inverse Association of Psoriasis and Life's Crucial 9 in US Adults: An Analysis from NHANES.https://www.psoriasis-news.de/articles.html/1_articles/the-inverse-association-of-psoriasis-and-lifes-crucial-9-in-us-adults-an-analysis-from-nhanes-r387/BackgroundLife's Crucial 9 (LC9) is a new tool used to evaluate cardiovascular health. At present, no studies have reported the association between LC9 and psoriasis.

Methods

This cross-sectional study utilized data from the National Health and Nutrition Examination Survey (NHANES) conducted between 2009 and 2014. The LC9 score was calculated based on the American Heart Association's recommendations and the Patient Health Questionnaire-9 assessment. Psoriasis status was identified using self-reported questionnaires. Weighted multivariable logistic regression and restricted cubic splines were applied to assess the association between LC9 and psoriasis. Subgroup analyses were conducted for each covariate, and the interaction between LC9 and potential confounders was examined. Additionally, sensitivity analyses were performed to assess the robustness of the results.

Results

A total of 11,762 participants aged 20 years and older were included in this study. After comprehensive adjustments, a negative linear association was observed between psoriasis and LC9: Each 10-point increment in LC9 corresponded to an odds ratio (OR) of 0.87 (95% CI: 0.78-0.96) for psoriasis. Relative to participants in the lowest LC9 quartile (Q1), the ORs for psoriasis were 0.73 (95% CI: 0.55-0.96) for Q3 and 0.55 (95% CI: 0.36-0.85) for Q4. Among participants aged 45 to 64 years, those in the highest LC9 quartile (Q4) had an adjusted OR of 0.42 (95% CI: 0.23-0.78). Heavy drinkers in Q4 exhibited an adjusted OR of 0.37 (95% CI: 0.15-0.92). Sensitivity analyses confirmed these results.

Conclusion

A linear negative relationship between psoriasis and LC9 was identified in this study. This observational result suggesting that enhancing LC9-related cardiovascular health factors may serve as an effective approach for psoriasis prevention and management.

Weiterlesen

]]>387Sun, 21 Dec 2025 14:44:00 +0000Increased Risk of Hematologic Malignancy in Moderate to Severe Psoriasis in Relation to the Use of Systemic Immunosuppressants: A Nationwide Population-Based Matched Cohort Study.https://www.psoriasis-news.de/articles.html/1_articles/increased-risk-of-hematologic-malignancy-in-moderate-to-severe-psoriasis-in-relation-to-the-use-of-systemic-immunosuppressants-a-nationwide-population-based-matched-cohort-study-r386/BackgroundThe relationship between cancer and the use of systemic immunosuppressants in psoriasis treatment has not well established. The aim of this study was to evaluate the association between the systemic immunosuppressants used in the treatment for psoriasis and the risk of certain cancers in Korean patients with moderate to severe psoriasis.

Methods

A retrospective cohort study was conducted involving 93,152 patients with moderate to severe psoriasis and 205,850 matched controls in Korea, using merged data from the National Health Insurance System, Health Insurance Review & Assessment Service, and Korea National Cancer Incidence Database from 2008 to 2018.

Results

The study observed a lower incidence of any cancer in moderate to severe psoriasis patients (2.4%) compared to the general population (2.99%). However, there was a higher risk of hematologic cancers, particularly Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, and cutaneous T cell lymphoma. Notably, methotrexate doses of ≥ 17.5 mg/week increased the risk of hematologic cancer risk by 7.546 times and cutaneous T cell lymphoma risk by 9.038 times, but cyclosporine and corticosteroids use did not show a significant association with increased incidence of hematologic cancers. Meanwhile, use of cyclosporine, methotrexate and corticosteroid did not significantly affect the risk of skin cancer among patients with psoriasis.

Conclusion

This study reveals an increased risk of hematologic cancers, such as cutaneous T cell lymphomas, associated with high-dose immunosuppressant use in moderate to severe psoriasis, underscoring the need for careful treatment management.

Weiterlesen

]]>386Sun, 21 Dec 2025 14:44:00 +0000Evaluation of netrin 1 as a new biomarker in the differentiation of psoriatic arthritis from psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/evaluation-of-netrin-1-as-a-new-biomarker-in-the-differentiation-of-psoriatic-arthritis-from-psoriasis-r385/Weiterlesen

]]>385Sun, 21 Dec 2025 14:44:00 +0000